| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Brivaracetam | Brivaracetam (alfaR, 4S)-Isomer | VE0011126 | View CAS 357336-99-3 |
| Brivaracetam | Brivaracetam Acid Impurity | VL4680001 | View CAS 943986-67-2 |
| Brivaracetam | Brivaracetam Impurity 1 | VE0012903 | View CAS 112106-16-8 |
| Brivaracetam | Brivaracetam Impurity 12 | VE0012919 | View |
| Brivaracetam | Brivaracetam Impurity 23 | VE0012920 | View |
| Brivaracetam | Brivaracetam Impurity 3 | VE0012904 | View CAS 2432911-34-5 |
| Brivaracetam | Brivaracetam Impurity 4 | VE0012050 | View CAS 63095-51-2 |
| Brivaracetam | Brivaracetam Impurity 5 | VE0012905 | View CAS 1942054-60-5 |
| Brivaracetam | Brivaracetam Impurity 6 | VE0012049 | View CAS 1956435-91-8 |
| Brivaracetam | Brivaracetam Impurity 7 (HCl Salt) | VE0012906 | View CAS 357338-46-6 |
| Brivaracetam | Brivaracetam Impurity 9 | VE0012917 | View CAS 2432911-32-3 |
| Brivaracetam | rac-Brivaracetam-D7 (Mixture of Diastereomers) | DVE00248 | View |
| Brivaracetam | 1-(1-carboxypropyl)-5-oxopyrrolidine-3-carboxylic acid | VE0010192 | View |
| Brivaracetam | 4-Propylpyrrolidin-2-one | VE0010191 | View CAS 89895-19-2 |
| Brivaracetam | (2R)-2-[(4R)-2-Oxo-4-propylpyrrolidin-1-yl]butanamide | VE0010072 | View CAS 357337-00-9 |
| Brivaracetam | (2S)-2-[(4S)-2-Oxo-4-propylpyrrolidin-1-yl]butanoic Acid | VE009871 | View CAS 2165431-90-1 |
Brivaracetam Related Compound
As long as you continue using it, this medication merely controls seizures; it cannot treat epilepsy. Persons with epilepsy aged 4 years and older continue to develop seizures while using various anti-seizure drugs to treat and prevent partial-onset seizures.
References
- Khaleghi, Farbod, and Eric C. Nemec. “Brivaracetam (Briviact): A Novel Adjunctive Therapy for Partial-Onset Seizures.” P & T : A Peer-Reviewed Journal for Formulary Management, vol. 42, no. 2, 2017, pp. 92–96, www.ncbi.nlm.nih.gov/pmc/articles/PMC5265234/#:~:text=While%20the%20exact%20mechanism%20of,implicated%20in%20synaptic%20signal%20transduction. Accessed 31 Aug. 2023.
- Kotloski, Robert J., et al. “Epilepsy and Aging.” Handbook of Clinical Neurology, Jan. 2019, pp. 455–75, https://doi.org/10.1016/b978-0-12-804766-8.00025-x. Accessed 31 Aug. 2023.
FAQ
What is the therapeutic class of brivaracetam?
Brivaracetam is an anticonvulsant used to treat partial-onset seizures. It works by attaching to the brain’s SV2A synaptic vesicle glycoprotein.
What is brivaracetam used for in psychiatry?
Comparing the incidence of depression and violence after BRV therapy to all prior patient group trials, a greater incidence was reported. However, in epileptic patients with mental comorbidities, BRV medication was demonstrated to lessen the aggressive and depressed symptoms connected to prior LEV treatment.
What is the mechanism of action of brivaracetam?
Brivaracetam’s specific mode of action is uncertain, however, it is thought that its anticonvulsant properties result from its extremely selective affinity for synaptic vesicle protein 2A (SV2A) in the brain. A protein-coding gene called SV2A glycoprotein is connected to synaptic signal transmission.
